Effect and Mechanism of Modified Buzhong Yiqi Tang and Pursed-lips Breathing on Serum TNF-α，IL-8，IL-6，IL-1β and Cys-C in Patients at Stable Stage of COPD
10.13422/j.cnki.syfjx.20191625
- VernacularTitle: 补中益气汤加味联合缩唇呼吸疗法对慢性阻塞性肺疾病稳定期患者血清TNF-α，IL-8，IL-6，IL-1β，Cys-C的影响
- Author:
Ming-ru HUANG
1
;
Zhong-bo XU
2
;
Fan HE
1
;
Tian-fu OUYANG
3
;
Ming-liang XU
4
Author Information
1. Jiangxi University of Traditional Chinese Medicine(TCM), Nanchang 330004, China
2. The Affiliated Hospital of Jiangxi University of TCM, Nanchang 330006, China
3. Basic Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
4. College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China
- Publication Type:Research Article
- Keywords:
chronic obstructive pulmonary disease(COPD);
stable period;
Buzhong Yiqi Tang;
pursed-lips Breathing (PLB);
inflammatory cytokines;
serum cystatin-C(Cys-C)
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(22):60-65
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the effect and mechanism of modified Buzhong Yiqi Tang and pursed-lips breathing (PLB) on serum tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), IL-6, IL-1β and serum cystatin C (Cys-C) in patients of chronic obstructive pulmonary disease (COPD) at the stable stage. Method: Totally 120 cases of COPD treated at Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine from September 2017 to March 2018 conformed to the inclusion criteria, and were randomly divided into treatment group (60 cases) and control group (60 cases). Cases of control group received Tiotropium (18 μg/time, qd). In addition to the therapy of control group, cases of treatment group were also given Buzhong Yiqi Tang and PLB. Both groups were treated for 6 months. Percent of forced expiratory volume in one second in predicted value (FEV1%), ratio of FEV1 to forced vital capacity (FEV1/FVC), six-minute walk distance (6MWD),TNF-α, IL-8, IL-6, IL-1β and Cys-C were compared between both groups. Result: After treatment, the clinical efficacy rate of observation group was 93.33%, which was evidently higher than 86.67%of control group (P<0.05). Compared with before treatment, both groups showed decreases in TNF-a,IL-8, IL-6,IL-1β, Cys-C but increases in FEV1%, FEV1/FVC (P<0.05). Compared with control group, treatment group showed decreases in TNF-a, IL-8, IL-6, IL-1β, Cys-C but increases in FEV1%, FEV1/FVC (P<0.05). Conclusion: Buzhong Yiqi Tang and PLB has an anti-inflammatory effect on COPD by reducing levels of inflammation cytokines TNF-α, IL-8,IL-6, IL-1β and chronic inflammation markers serum Cys-C and inflammatory reaction, and alleviating airflow obstruction, promoting the levels of FEV1%, FEV1/FVC, pulmonary function control inflammatory factors, so as to improve pulmonary function and the quality of life in patients with COPD.
